文献速递白血病

一种抗CD3/抗CLL-1双特异性抗体用于治疗急性髓系白血病

An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia.
PubMed 文献 · Blood · 2016-12-01

本文描述靶向CLL-1的CD3 T细胞依赖性双特异性全长人IgG1治疗抗体的设计、发现、药理活性、药代动力学和安全性;高亲和力CD3臂体外活性强达100倍,但仅低亲和力CD3/CLL1双特异性抗体在猴中耐受良好并能清除靶细胞。

要点

  • CLL-1在AML中普遍表达且不表达于造血干细胞,具有造血恢复潜力。
  • 高亲和力CD3臂体外活性强达100倍,但小鼠模型中疗效差异较小。
  • 仅低亲和力CD3/CLL1双特异性抗体在猴中耐受良好并能清除靶细胞。

核心结论

  • 数据提示经适当工程化设计的CLL-1双特异性抗体可能对急性髓系白血病治疗有效。

研究设计与样本

  • 本文描述靶向CLL-1的CD3 T细胞依赖性双特异性全长人IgG1治疗抗体的设计、发现、药理活性、药代动力学和安全性。

主要发现

  • 高亲和力CD3臂体外活性比低亲和力CD3臂强达100倍。
  • 小鼠模型中高亲和力与低亲和力CD3双特异性抗体的疗效差异较小,可能因低亲和力CD3双特异性抗体暴露时间延长。
  • 猴中高亲和力和低亲和力双特异性抗体的安全性与靶细胞清除评估显示,仅低亲和力CD3/CLL1双特异性抗体耐受良好并能清除靶细胞。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML) is a major unmet medical need. Most patients have poor long-term survival, and treatment has not significantly changed in 40 years. Recently, bispecific antibodies that redirect the cytotoxic activity of effector T cells by binding to CD3, the signaling component of the T-cell receptor, and a tumor target have shown clinical activity. Notably, blinatumomab is approved to treat relapsed/refractory acute lymphoid leukemia. Here we describe the design, discovery, pharmacologic activity, pharmacokinetics, and safety of a CD3 T cell-dependent bispecific (TDB) full-length human IgG1 therapeutic antibody targeting CLL-1 that could potentially be used in humans to treat AML. CLL-1 is prevalent in AML and, unlike other targets such as CD33 and CD123, is not expressed on hematopoietic stem cells providing potential hematopoietic recovery. We selected a high-affinity monkey cross-reactive anti-CLL-1 arm and tested several anti-CD3 arms that varied in affinity, and determined that the high-affinity CD3 arms were up to 100-fold more potent in vitro. However, in mouse models, the efficacy differences were less pronounced, probably because of prolonged exposure to TDB found with lower-affinity CD3 TDBs. In monkeys, assessment of safety and target cell depletion by the high- and low-affinity TDBs revealed that only the low-affinity CD3/CLL1 TDB was well tolerated and able to deplete target cells. Our data suggest that an appropriately engineered CLL-1 TDB could be effective in the treatment of AML.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Leong SR, Sukumaran S, Hristopoulos M, et al. An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia. Blood. 2016. PMID: 27908880. doi:10.1182/blood-2016-08-735365

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。